Wesley R. Armstrong

1.6k total citations · 1 hit paper
39 papers, 525 citations indexed

About

Wesley R. Armstrong is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Wesley R. Armstrong has authored 39 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 25 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Oncology. Recurrent topics in Wesley R. Armstrong's work include Prostate Cancer Treatment and Research (33 papers), Radiopharmaceutical Chemistry and Applications (23 papers) and Prostate Cancer Diagnosis and Treatment (18 papers). Wesley R. Armstrong is often cited by papers focused on Prostate Cancer Treatment and Research (33 papers), Radiopharmaceutical Chemistry and Applications (23 papers) and Prostate Cancer Diagnosis and Treatment (18 papers). Wesley R. Armstrong collaborates with scholars based in United States, Germany and Italy. Wesley R. Armstrong's co-authors include Jérémie Calais, Johannes Czernin, Matthias Eiber, Wolfgang P. Fendler, Tristan Grogan, Ken Herrmann, Matthias Benz, Andrei Gafita, Manuel Weber and Wolfgang Weber and has published in prestigious journals such as Journal of Clinical Oncology, Immunity and Scientific Reports.

In The Last Decade

Wesley R. Armstrong

36 papers receiving 525 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging

2025 19 citations Adrien Holzgreve, Wesley R. Armstrong et al. JAMA Network Open profile →

Peers

Countries citing papers authored by Wesley R. Armstrong

Since Specialization

Citations

This map shows the geographic impact of Wesley R. Armstrong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wesley R. Armstrong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wesley R. Armstrong more than expected).

Fields of papers citing papers by Wesley R. Armstrong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wesley R. Armstrong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wesley R. Armstrong. The network helps show where Wesley R. Armstrong may publish in the future.

Co-authorship network of co-authors of Wesley R. Armstrong

This figure shows the co-authorship network connecting the top 25 collaborators of Wesley R. Armstrong. A scholar is included among the top collaborators of Wesley R. Armstrong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wesley R. Armstrong. Wesley R. Armstrong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The transcriptional repressor Fli1 inhibits proteostasis during nutrient stress to limit NK cell persistence in solid tumors 2026 ·Immunity ·(unknown), Wesley R. Armstrong, Joey H. Li, (unknown), (unknown), (unknown), (unknown), (unknown), Alexander Muir, Timothy E. O’Sullivan	0
2	Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study 2025 ·Journal of Nuclear Medicine ·Lena M. Unterrainer, Thomas A. Hope, Wolfgang P. Fendler, Tristan Grogan, Honest Ndlovu, Wesley R. Armstrong, Francesco Barbato, Matthias Benz, Matthew B. Rettig, Amar U. Kishan, Mike Sathekge, (unknown), Johannes Czernin, Jérémie Calais	5
3	PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging breakdown → 2025 ·JAMA Network Open ·Adrien Holzgreve, Wesley R. Armstrong, (unknown), Matthias Benz, Clayton Smith, Loïc Djaileb, (unknown), Pan Thin, Nicholas G. Nickols, Amar U. Kishan, Matthew B. Rettig, Robert E. Reiter, Johannes Czernin, Jérémie Calais	19
4	Species-specific serine metabolism differentially controls natural killer cell functions 2025 ·Nature Metabolism ·Joey H. Li, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Wesley R. Armstrong, (unknown), Abigail S. Krall, (unknown), Tara TeSlaa, Heather R. Christofk, Ajit S. Divakaruni, Timothy E. O’Sullivan	0
5	Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: A single-center retrospective study 2025 ·Radiotherapy and Oncology ·Masatoshi Hotta, Kathleen Nguyen, Pan Thin, Wesley R. Armstrong, Ida Sonni, Andrea Farolfi, Michael L. Steinberg, Johannes Czernin, Nicholas G. Nickols, Amar U. Kishan, Jérémie Calais	2
6	Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy 2024 ·Scientific Reports ·(unknown), Andrei Gafita, Matthias Benz, Loïc Djaileb, Andrea Farolfi, Masatoshi Hotta, Ida Sonni, (unknown), Matthew B. Rettig, John Shen, Wesley R. Armstrong, Tristan Grogan, Sandy Liu, Johannes Czernin, Jérémie Calais	4
7	Differences and Common Ground in¹⁷⁷Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers 2024 ·Journal of Nuclear Medicine ·Andrea Farolfi, Wesley R. Armstrong, Loïc Djaileb, Andrei Gafita, Masatoshi Hotta, Martin Allen-Auerbach, Lena M. Unterrainer, Wolfgang P. Fendler, Matthew B. Rettig, Matthias Eiber, Michael S. Hofman, Boris Hadaschik, Ken Herrmann, Johannes Czernin, Jérémie Calais, Matthias Benz	9
8	Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774) 2024 ·European Urology ·Wesley R. Armstrong, Amar U. Kishan, (unknown), Tristan Grogan, David Elashoff, (unknown), (unknown), Michael L. Steinberg, Wolfgang P. Fendler, Thomas A. Hope, Nicholas G. Nickols, Johannes Czernin, Jérémie Calais	12
9	Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease 2024 ·Journal of Nuclear Medicine ·Masatoshi Hotta, Grace Hyun J. Kim, (unknown), (unknown), Wesley R. Armstrong, Giuseppe Carlucci, Magnus Dahlbom, Fereidoun Abtin, (unknown), Gregory A. Fishbein, Johannes Czernin, Elizabeth R. Volkmann, S. Sam Weigt, Jérémie Calais	5
10	Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials 2023 ·International Journal of Radiation OncologyBiologyPhysics ·Clayton Smith, Michael Xiang, Wesley R. Armstrong, Nicholas G. Nickols, Michael L. Steinberg, Robert E. Reiter, Matthew B. Rettig, Adam B. Weiner, John Shen, Luca Valle, Johannes Czernin, Jérémie Calais, Amar U. Kishan	10
11	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study 2022 ·Journal of Nuclear Medicine ·Andrei Gafita, Isabel Rauscher, Manuel Weber, Boris Hadaschik, Hui Wang, Wesley R. Armstrong, Robert Tauber, Tristan Grogan, Johannes Czernin, Matthew B. Rettig, Ken Herrmann, Jérémie Calais, Wolfgang Weber, Matthias Benz, Wolfgang P. Fendler, Matthias Eiber	90
12	Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management: Results from the Prospective Randomized Phase 3 Trial [PSMA SRT NCT03582774] 2022 ·International Journal of Radiation OncologyBiologyPhysics ·Wesley R. Armstrong, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jérémie Calais	1
13	¹⁸F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma 2021 ·Journal of Nuclear Medicine ·Joseph G. Crompton, Wesley R. Armstrong, Mark A. Eckardt, (unknown), William D. Tap, Sarah Dry, Evan R. Abt, Jérémie Calais, Ken Herrmann, Johannes Czernin, Fritz C. Eilber, Matthias Benz	2
14	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study 2021 ·Journal of Nuclear Medicine ·Justin Ferdinandus, Wolfgang P. Fendler, Andrea Farolfi, Samuel L. Washington, Osama Mohamad, Miguel Hernandez Pampaloni, Peter J. H. Scott, Melissa E. Rodnick, Benjamin L. Viglianti, Matthias Eiber, Ken Herrmann, Johannes Czernin, Wesley R. Armstrong, Jérémie Calais, Thomas A. Hope, Morand Piert	24
15	A Comprehensive Assessment of ⁶⁸Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients 2021 ·Journal of Nuclear Medicine ·(unknown), Wesley R. Armstrong, Kathleen Nguyen, Jérémie Calais, Johannes Czernin, (unknown), (unknown), Melissa E. Rodnick, Thomas A. Hope, Jason W.D. Hearn, Jeffrey S. Montgomery, Ajjai Alva, Zachery R. Reichert, Daniel E. Spratt, Timothy D. Johnson, Peter J. H. Scott, Morand Piert	23
16	Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312) 2021 ·Journal of Nuclear Medicine ·Jérémie Calais, Johannes Czernin, Pan Thin, J Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, (unknown), Magnus Dahlbom, (unknown), Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler, Ebrahim S. Delpassand	29
17	Head-to-Head Comparison of⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial 2021 ·Journal of Nuclear Medicine ·Ida Sonni, Ely Felker, Andrew T. Lenis, Anthony Sisk, Shadfar Bahri, Martin Allen-Auerbach, Wesley R. Armstrong, (unknown), (unknown), Tristan Grogan, David Elashoff, Matthias Eiber, Steven S. Raman, Johannes Czernin, Robert E. Reiter, Jérémie Calais	87
18	The Impact of Monosodium Glutamate on ⁶⁸Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study 2021 ·Journal of Nuclear Medicine ·Wesley R. Armstrong, Andrei Gafita, Shaojun Zhu, Pan Thin, Kathleen Nguyen, (unknown), (unknown), (unknown), (unknown), Tristan Grogan, David Elashoff, Martin Allen-Auerbach, Magnus Dahlbom, Johannes Czernin, Jérémie Calais	11
19	Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome 2020 ·European Urology Focus ·Jérémie Calais, Wesley R. Armstrong, Amar U. Kishan, (unknown), Thomas A. Hope, Wolfgang P. Fendler, David Elashoff, Nicholas G. Nickols, Johannes Czernin	25
20	Total-Body ⁶⁸Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines 2019 ·Journal of Nuclear Medicine ·Kelsey L. Pomykala, Johannes Czernin, Tristan Grogan, Wesley R. Armstrong, John Williams, Jérémie Calais	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact